These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
468 related articles for article (PubMed ID: 36235607)
1. Trimethylamine-N-Oxide Promotes Osteoclast Differentiation and Bone Loss via Activating ROS-Dependent NF-κB Signaling Pathway. Wang N; Hao Y; Fu L Nutrients; 2022 Sep; 14(19):. PubMed ID: 36235607 [TBL] [Abstract][Full Text] [Related]
2. Trimethylamine-N-oxide promotes osteoclast differentiation and oxidative stress by activating NF-κB pathway. Zhao Y; Wang C; Qiu F; Liu J; Xie Y; Lin Z; He J; Chen J Aging (Albany NY); 2024 May; 16(10):9251-9263. PubMed ID: 38809508 [TBL] [Abstract][Full Text] [Related]
3. Acteoside suppresses RANKL-mediated osteoclastogenesis by inhibiting c-Fos induction and NF-κB pathway and attenuating ROS production. Lee SY; Lee KS; Yi SH; Kook SH; Lee JC PLoS One; 2013; 8(12):e80873. PubMed ID: 24324641 [TBL] [Abstract][Full Text] [Related]
4. Nrf2 deficiency induces oxidative stress and promotes RANKL-induced osteoclast differentiation. Hyeon S; Lee H; Yang Y; Jeong W Free Radic Biol Med; 2013 Dec; 65():789-799. PubMed ID: 23954472 [TBL] [Abstract][Full Text] [Related]
5. Ginsenoside Rb2 inhibits osteoclast differentiation through nuclear factor-kappaB and signal transducer and activator of transcription protein 3 signaling pathway. Cong F; Liu J; Wang C; Yuan Z; Bi L; Liang J; Su K; Qiu Y; Song T; Fan J; Chao G Biomed Pharmacother; 2017 Aug; 92():927-934. PubMed ID: 28605877 [TBL] [Abstract][Full Text] [Related]
6. NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. Yamashita T; Yao Z; Li F; Zhang Q; Badell IR; Schwarz EM; Takeshita S; Wagner EF; Noda M; Matsuo K; Xing L; Boyce BF J Biol Chem; 2007 Jun; 282(25):18245-18253. PubMed ID: 17485464 [TBL] [Abstract][Full Text] [Related]
7. Urolithin B suppressed osteoclast activation and reduced bone loss of osteoporosis via inhibiting ERK/NF-κB pathway. Li Y; Zhuang Q; Tao L; Zheng K; Chen S; Yang Y; Feng C; Wang Z; Shi H; Shi J; Fang Y; Xiao L; Geng D; Wang Z Cell Prolif; 2022 Oct; 55(10):e13291. PubMed ID: 35708050 [TBL] [Abstract][Full Text] [Related]
8. Norisoboldine suppresses osteoclast differentiation through preventing the accumulation of TRAF6-TAK1 complexes and activation of MAPKs/NF-κB/c-Fos/NFATc1 Pathways. Wei ZF; Tong B; Xia YF; Lu Q; Chou GX; Wang ZT; Dai Y PLoS One; 2013; 8(3):e59171. PubMed ID: 23536866 [TBL] [Abstract][Full Text] [Related]
9. Total saponin from Anemone flaccida Fr. Schmidt abrogates osteoclast differentiation and bone resorption via the inhibition of RANKL-induced NF-κB, JNK and p38 MAPKs activation. Kong X; Wu W; Yang Y; Wan H; Li X; Zhong M; Zhao H; Su X; Jia S; Ju D; Lin N J Transl Med; 2015 Mar; 13():91. PubMed ID: 25889035 [TBL] [Abstract][Full Text] [Related]
10. Euphorbia factor L1 inhibits osteoclastogenesis by regulating cellular redox status and induces Fas-mediated apoptosis in osteoclast. Hong SE; Lee J; Seo DH; In Lee H; Ri Park D; Lee GR; Jo YJ; Kim N; Kwon M; Shon H; Kyoung Seo E; Kim HS; Young Lee S; Jeong W Free Radic Biol Med; 2017 Nov; 112():191-199. PubMed ID: 28774817 [TBL] [Abstract][Full Text] [Related]
11. GSH attenuates RANKL-induced osteoclast formation in vitro and LPS-induced bone loss in vivo. Han B; Geng H; Liu L; Wu Z; Wang Y Biomed Pharmacother; 2020 Aug; 128():110305. PubMed ID: 32485573 [TBL] [Abstract][Full Text] [Related]
12. Zanthoxylum piperitum alleviates the bone loss in osteoporosis via inhibition of RANKL-induced c-fos/NFATc1/NF-κB pathway. Kim MH; Lee H; Ha IJ; Yang WM Phytomedicine; 2021 Jan; 80():153397. PubMed ID: 33130475 [TBL] [Abstract][Full Text] [Related]
13. Bergapten suppresses RANKL-induced osteoclastogenesis and ovariectomy-induced osteoporosis via suppression of NF-κB and JNK signaling pathways. Chen G; Xu Q; Dai M; Liu X Biochem Biophys Res Commun; 2019 Feb; 509(2):329-334. PubMed ID: 30579598 [TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitor CI-994 inhibits osteoclastogenesis via suppressing NF-κB and the downstream c-Fos/NFATc1 signaling pathways. Guo D; Hong D; Wang P; Wang J; Chen L; Zhao W; Zhang L; Yao C; Chu B; Chen S; Li Z; Chen H Eur J Pharmacol; 2019 Apr; 848():96-104. PubMed ID: 30682334 [TBL] [Abstract][Full Text] [Related]
15. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos. He L; Lee J; Jang JH; Lee SH; Nan MH; Oh BC; Lee SG; Kim HH; Soung NK; Ahn JS; Kim BY Bone; 2012 Jun; 50(6):1207-13. PubMed ID: 22484180 [TBL] [Abstract][Full Text] [Related]
16. Monotropein Protects against Inflammatory Bone Loss and Suppresses Osteoclast Formation and Bone Resorption by Inhibiting NFATc1 via NF-κB and Akt/GSK-3β Pathway. Zhang Q; Hu S; He Y; Song Z; Shen Y; Zhao Z; Zhang Q; Qin L; Zhang Q Nutrients; 2022 Sep; 14(19):. PubMed ID: 36235631 [TBL] [Abstract][Full Text] [Related]
18. Esculetin attenuates receptor activator of nuclear factor kappa-B ligand-mediated osteoclast differentiation through c-Fos/nuclear factor of activated T-cells c1 signaling pathway. Baek JM; Park SH; Cheon YH; Ahn SJ; Lee MS; Oh J; Kim JY Biochem Biophys Res Commun; 2015 May; 461(2):334-41. PubMed ID: 25887803 [TBL] [Abstract][Full Text] [Related]
19. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways. Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253 [TBL] [Abstract][Full Text] [Related]
20. Specnuezhenide suppresses diabetes-induced bone loss by inhibiting RANKL-induced osteoclastogenesis. Ye X; Jiang J; Yang J; Yan W; Jiang L; Chen Y Acta Biochim Biophys Sin (Shanghai); 2022 Aug; 54(8):1080-1089. PubMed ID: 35929595 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]